TABLE 2.

Comparison of patients' characteristics between patients with or without liver metastasis

Characteristic	Male		p	Female		p
	With liver metastasis, n (%)	Without liver metastasis, n (%)		With liver metastasis, n (%)	Without liver metastasis, n (%)
Age			0.490			0.710
>60	21 (28.0)	11 (35.5)		7 (14.0)	2 (8.7)
≤60	54 (72.0)	20 (64.5)		43 (86.0)	21 (91.3)
Primary tumor location			0.748			0.022
Right‐sided	19 (25.3)	10 (32.3)		20 (40.0)	6 (26.1)
Left‐sided	31 (41.3)	11 (35.5)		23 (46.0)	7 (30.4)
Rectum	25 (33.3)	10 (32.3)		7 (14.0)	10 (43.5)
Metastasis site
Lung			0.134			0.449
Involved	41 (54.7)	22 (71.0)		27 (54.0)	15 (65.2)
Noninvolved	34 (45.3)	9 (29.0)		23 (46.0)	8 (34.8)
Distant lymph node			0.659			0.214
Involved	29 (38.7)	10 (32.3)		22 (44.0)	14 (60.9)
Noninvolved	46 (61.3)	21 (67.7)		28 (56.0)	9 (39.1)
Peritoneal			<0.001			0.204
Involved	16 (21.3)	19 (61.3)		19 (38.0)	13 (56.5)
Noninvolved	59 (78.7)	12 (38.7)		31 (62.0)	10 (43.5)
RAS			0.286			0.447
Wild‐type	39 (52.0)	12 (38.7)		20 (40.0)	12 (52.2)
Mutated	36 (48.0)	19 (61.3)		30 (60.0)	11 (47.8)
BRAF			0.625			0.213
Wild‐type	69 (92.0)	27 (87.1)		48 (96.0)	22 (95.7)
V600E mutated	4 (5.3)	2 (6.5)		2 (4.0)	0 (0)
Non‐ V600E mutated	2 (2.7)	2 (6.5)		0 (0)	1 (4.3)
Homologous recombination deficiency			0.004			1.000
Yes	4 (9.8)	8 (44.4)		5 (17.2)	2 (15.4)
No	37 (90.2)	10 (55.6)		24 (82.8)	11 (84.6)
Response			0.056			0.065
Complete response	0 (0)	0 (0)		0 (0)	0 (0)
Partial response	3 (4.0)	4 (12.9)		0 (0)	0 (0)
Stable disease	26 (34.7)	15 (48.4)		14 (28.0)	12 (52.2)
Progressive disease	46 (61.3)	12 (38.7)		36 (72.0)	11 (47.8)